Fruquintinib

Fruquintinib
Clinical data
Trade names	Fruzaqla
Other names	HMPL-013
License data	US DailyMed: Fruquintinib;
Routes of; administration	By mouth
Drug class	Antineoplastic
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name 6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-N,2-dimethyl-1-benzofuran-3-carboxamide;
CAS Number	1194506-26-7;
PubChem CID	44480399;
DrugBank	DB11679;
ChemSpider	39625837;
UNII	49DXG3M5ZW;
KEGG	D11977;
Chemical and physical data
Formula	C21H19N3O5
Molar mass	393.399 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC(=O)C1=C(C)OC2=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=CC=C12;
	InChI InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25); Key:BALLNEJQLSTPIO-UHFFFAOYSA-N;

Fruquintinib, sold under the brand name Fruzaqla, is an anti-cancer medication used for the treatment of colorectal cancer.^[1] Fruquintinib is a kinase inhibitor.^[1]

Fruquintinib was approved for medical use in the United States in November 2023.^[2]^[3]

Medical uses

Fruquintinib is indicated for adults with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.^[1]^[2]

References

^ ^a ^b ^c ^d https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf
^ ^a ^b "FDA approves fruquintinib in refractory metastatic colorectal cancer". U.S. Food and Drug Administration (FDA). 8 November 2023. Retrieved 10 November 2023. This article incorporates text from this source, which is in the public domain.
^ "Takeda Receives U.S. FDA Approval of Fruzaqla (fruquintinib) for Previously Treated Metastatic Colorectal Cancer" (Press release). Takeda. 8 November 2023. Retrieved 10 November 2023 – via Business Wire.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Fruzaqla_FDA_label-1] ttps://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf

[FDA_fruquintinib-2] "FDA approves fruquintinib in refractory metastatic colorectal cancer". U.S. Food and Drug Administration (FDA). 8 November 2023. Retrieved 10 November 2023. This article incorporates text from this source, which is in the public domain.

[3] "Takeda Receives U.S. FDA Approval of Fruzaqla (fruquintinib) for Previously Treated Metastatic Colorectal Cancer" (Press release). Takeda. 8 November 2023. Retrieved 10 November 2023 – via Business Wire.

[1]

[2]

[3]